Skyrizi® (risankizumab-rzaa)

BL 761105 [BL 761262]

Skyrizi® (risankizumab-rzaa)

BL 761105 [BL 761262]

U.S. License Holder:

AbbVie Inc.

Date of License:

April-23-2019

Last Update:

Dec-15-2024

approved_indications FDA-Approved Indications

SKYRIZI (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of:

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy;

Active psoriatic arthritis in adults;

Moderately to severely active Crohn's disease in adults;

Moderately to severely active ulcerative colitis in adults.

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

PGR2022-00037

U.S. Patent No.
11,078,265 (Anti-IL-23 Antibodies)

Patent Owner
Boehringer Ingelheim International GmbH

Petitioner(s)
Sandoz, Inc.; Sandoz AG

§ 102 Challenge
N

§ 103 challenge
N

IPR Status
Challenges Include Written Description (Claims 7-10, 14-16, 19-22, 27-28) and Enablement (Claims 7-10, 14-16, 19-22, 27-28). Institution Denied, Request for Rehearing Denied

Related News

What Do the Humira Biosimilar / Interchangeable Launches Mean for the Adalimumab Market?
April Breyer Menon Ha Kung Wong
August 7, 2023
Venable’s BiologicsHQ Monthly Injection – February 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 15, 2023
Venable’s BiologicsHQ Monthly Injection – December 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2023
Venable’s BiologicsHQ Monthly Injection – November 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
December 14, 2022
Venable’s BiologicsHQ Monthly Injection – May 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 7, 2022
Venable’s BiologicsHQ Monthly Injection – April 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
May 7, 2019

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha